Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric ADHD Clear all
Active, not recruiting Not applicable Interventional

tRNS Treatment for ADHD Symptoms

NCT06189703
View directory record Official record
Conditions
ADHD
Interventions
tRNS
Device
Lead sponsor
Innosphere
Industry
Eligibility
7 Years to 12 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

NCT07061470
View directory record Official record
Conditions
ADHD, Sleep Problems
Interventions
Ferrous Sulfate, Placebo
Dietary Supplement · Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional

Impact of Parental Emotion Regulation on the Treatment of ADHD

NCT05299814
View directory record Official record
Conditions
ADHD
Interventions
Behavioral Parenting Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 12 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study

NCT01506232
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional

Pediatric Epilepsy

NCT07350551
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

Dasotraline SEP360-105 Pediatric PK/PD Study

NCT02195167
View directory record Official record
Conditions
Pediatric Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT00318448
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 10, 2026, 2:40 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT02736656
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
16
States / cities
Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Enrolling by invitation No phase listed Observational

Pediatric Behavioral Health Integrated Care: Indiana Statewide Strategic Plan to Address the Growing Mental Health Crisis

NCT07216638
View directory record Official record
Conditions
Implementation Research, Depressive Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Conduct Disorders in Children, Pediatric Mental Health Services
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
5 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Not applicable Interventional

Evaluating an Online Parenting Support System Disseminated by Pediatric Practices

NCT02064452
View directory record Official record
Conditions
Child Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Triple P Online System, Placebo Comparator
Other · Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
3 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Eugene, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional

Virtual Reality Attention Management

NCT03221244
View directory record Official record
Conditions
ADHD
Interventions
VR Treatment, VR Active Control
Device
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Not yet recruiting Phase 4 Interventional

EEG Biomarkers for ADHD Stimulant Treatment

NCT07650643
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl, Mixed amphetamine salts extended release
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Active, not recruiting Not applicable Interventional

Optimizing Attention and Sleep Intervention Study

NCT05683756
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Hyperactivity Disorder, Child, Preschool, Sleep, Sleep Disturbance
Interventions
Brief Parent Behavioral Intervention, Sleep-Focused Parent Behavioral Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
3 Years to 5 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Cranberry Township, Pennsylvania • Monroeville, Pennsylvania • New Castle, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional

SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care

NCT04946253
View directory record Official record
Conditions
Child Behavior Problem, Attention Deficit and Disruptive Behavior Disorders
Interventions
DOCC: Evidence-based treatment for disruptive behavior and ADHD, TEAM: Implementation support strategies at the care team level following standard implementation of DOCC, Implementation support strategies at the leadership level following standard implementation of DOCC
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 2 Interventional

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

NCT00466791
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

NCT00301236
View directory record Official record
Conditions
ADHD, ADD
Interventions
Dexmethylphenidate HCl extended-release capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
252 participants
Timeline
2006
U.S. locations
25
States / cities
Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting No phase listed Observational

Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder

NCT00025935
View directory record Official record
Conditions
Mood Disorder
Interventions
Lithium
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 85 Years
Enrollment
2,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD - Follow Up

NCT02828644
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
EVO
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 10, 2026, 2:40 PM EDT
Terminated Not applicable Interventional

Pharmacogenomics for Improving Pediatric ADHD Treatment

NCT03730870
View directory record Official record
Conditions
Attention Deficit Disorders With Hyperactivity
Interventions
Pharmacogenomics report
Diagnostic Test
Lead sponsor
Clinical and Translational Genome Research Institute, Inc.
Other
Eligibility
6 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 10, 2026, 2:40 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Characterization and Brain Mechanisms of Frustration in Youth With Severe Irritability or Attention Deficit Hyperactivity Disorder (ADHD)

NCT05357495
View directory record Official record
Conditions
Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder, Normal Physiology
Interventions
Affective Posner fMRI frustration induction task
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 10, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 10, 2026, 2:40 PM EDT
Completed No phase listed Observational

Pediatric Bipolar Disorder Study at UCLA

NCT00961935
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 10, 2026, 2:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 2:40 PM EDT